ESR1 and breast carcinoma: While combination inhibition with alpelisib, cetuximab, encorafenib, and binimetinib has been trialed in B-Raf proto-oncogene, serine/threonine kinase (BRAF)-mutant colorectal cancer, evidence for ER+ breast cancer is lacking [166].